Copper(ii) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cells.

A series of water-soluble sodium salts of 3-formyl-4-hydroxybenzenesulfonic acid thiosemicarbazones (or sodium 5-sulfonate-salicylaldehyde thiosemicarbazones) containing different substituents at the terminal nitrogen atom (H, Me, Et, Ph) and their copper(ii) complexes have been prepared and characterised by elemental analysis, spectroscopic techniques (IR, UV-vis, 1H NMR), ESI mass spectrometry, X-ray crystallography and cyclic voltammetry. The proligands and their copper(ii) complexes exhibit moderate water solubility and good stability in aqueous environment, determined by investigating their proton dissociation and complex formation equilibria. The copper(ii) complexes showed moderate anticancer activity in established human cancer cell lines, while the proligands were devoid of cytotoxicity. The anticancer activity of the copper(ii) complexes correlates with their ability to induce ROS accumulation in cells, consistent with their redox potentials within the biological window, triggering the activation of antioxidation defense mechanisms in response to the ROS insult. These studies pave the way for the investigation of ROS-inducing copper(ii) complexes as prospective antiproliferative agents in cancer chemotherapy.

[1]  Horace Traubel.  Collect , 1904, Walt Whitman Quarterly Review.

[2]  W. Hager,et al.  and s , 2019, Shallow Water Hydraulics.

[3]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[4]  Seyed Abolfazl Hosseini‐Yazdi,et al.  Synthesis, characterization and in vitro biological activities of new water-soluble copper(II), zinc(II), and nickel(II) complexes with sulfonato-substituted Schiff base ligand , 2017 .

[5]  Seyed Abolfazl Hosseini‐Yazdi,et al.  Reactions of copper(II), nickel(II), and zinc(II) acetates with a new water-soluble 4-phenylthiosemicarbazone Schiff base ligand: Synthesis, characterization, unexpected cyclization, antimicrobial, antioxidant, and anticancer activities , 2017 .

[6]  G. Mann,et al.  Cardioprotective effects of Cu(II)ATSM in human vascular smooth muscle cells and cardiomyocytes mediated by Nrf2 and DJ-1 , 2016, Scientific Reports.

[7]  M. Siegler,et al.  Copper-Catalyzed Oxidation of Alkanes with H2 O2 under a Fenton-like Regime. , 2016, Angewandte Chemie.

[8]  G. Spengler,et al.  Structure-antiproliferative activity studies on l-proline- and homoproline-4-N-pyrrolidine-3-thiosemicarbazone hybrids and their nickel(ii), palladium(ii) and copper(ii) complexes. , 2016, Dalton transactions.

[9]  Wei Chen,et al.  Metabolomics analysis reveals heavy metal copper-induced cytotoxicity in HT-29 human colon cancer cells , 2016 .

[10]  Emanuele Rossini,et al.  Proton solvation in protic and aprotic solvents , 2016, J. Comput. Chem..

[11]  Kowthar Y. Salim,et al.  COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo , 2016, Oncotarget.

[12]  M. Hemann,et al.  Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes. , 2016, Angewandte Chemie.

[13]  Y. Kumagai,et al.  Copper diethyldithiocarbamate as an activator of Nrf2 in cultured vascular endothelial cells , 2016, JBIC Journal of Biological Inorganic Chemistry.

[14]  D. Richardson,et al.  The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones. , 2015, Pharmacological research.

[15]  S. Mapolie,et al.  Water‐Soluble Palladium(II) Sulfonated Thiosemicarbazone Complexes: Facile Synthesis and Preliminary Catalytic Studies in the Suzuki–Miyaura Cross‐Coupling Reaction in Water , 2015 .

[16]  M. McDevitt,et al.  A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms , 2014, Haematologica.

[17]  D. B. Collum,et al.  Method of continuous variations: applications of job plots to the study of molecular associations in organometallic chemistry. , 2013, Angewandte Chemie.

[18]  J. Takahashi,et al.  Structural Studies and Investigation on the Activity of Imidazole-Derived Thiosemicarbazones and Hydrazones against Crop-Related Fungi , 2013, Molecules.

[19]  R. Bowler,et al.  Trolox contributes to Nrf2-mediated protection of human and murine primary alveolar type II cells from injury by cigarette smoke , 2013, Cell Death and Disease.

[20]  B. Keppler,et al.  Complex-Formation Ability of Salicylaldehyde Thiosemicarbazone towards ZnII, CuII, FeII, FeIII and GaIII Ions , 2012 .

[21]  M. Jakupec,et al.  L- and D-proline thiosemicarbazone conjugates: coordination behavior in solution and the effect of copper(II) coordination on their antiproliferative activity. , 2012, Inorganic chemistry.

[22]  N. Arnal,et al.  Cytotoxic effects of copper overload on human-derived lung and liver cells in culture. , 2012, Biochimica et biophysica acta.

[23]  W. Marsden.  I and J , 2012 .

[24]  W. Berger,et al.  Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds , 2012, JBIC Journal of Biological Inorganic Chemistry.

[25]  Rubén Gil-García,et al.  Pyridine-2-Carbaldehyde Thiosemicarbazonecopper System: Extending Some Findings to Other Thiosemicarbazone and Coordination Compounds , 2011 .

[26]  P. Chiba,et al.  Synthesis, structures and anti-malaria activity of some gold(I) phosphine complexes containing seleno- and thiosemicarbazonato ligands. , 2011, Dalton transactions.

[27]  H. Steinhagen.  The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. By Enrique Raviña. , 2011 .

[28]  W. Berger,et al.  Anticancer activity of metal complexes: involvement of redox processes. , 2011, Antioxidants & redox signaling.

[29]  D. Newton,et al.  A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. , 2011, Free radical biology & medicine.

[30]  G. Wilding,et al.  Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients , 2011, Cancer Chemotherapy and Pharmacology.

[31]  C. Marzano,et al.  Copper in diseases and treatments, and copper‐based anticancer strategies , 2009, Medicinal research reviews.

[32]  J. Fraser,et al.  Regulation and Function of the Original p53- Inducible p21 Gene , 2010 .

[33]  J. Kolesar,et al.  A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503 , 2010, Investigational New Drugs.

[34]  Donna D. Zhang,et al.  Nrf2 and p21 regulate the fine balance between life and death by controlling ROS levels , 2009, Cell cycle.

[35]  W. Berger,et al.  Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. , 2009, Journal of medicinal chemistry.

[36]  D. Richardson,et al.  Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. , 2009, Journal of medicinal chemistry.

[37]  Donna D. Zhang,et al.  Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. , 2009, Molecular cell.

[38]  S. K. Choudhuri,et al.  Detection and characterization of a glutathione conjugate of a novel copper complex. , 2009, In vivo.

[39]  Richard J. Gildea,et al.  OLEX2: a complete structure solution, refinement and analysis program , 2009 .

[40]  Ernst-Walter Knapp,et al.  Accurate redox potentials of mononuclear iron, manganese, and nickel model complexes* , 2009, J. Comput. Chem..

[41]  M. Sznol,et al.  A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. , 2008, Leukemia research.

[42]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[43]  G. Pond,et al.  A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium , 2007, Investigational New Drugs.

[44]  M. Jakupec,et al.  Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. , 2007, Journal of medicinal chemistry.

[45]  P. Schumacker,et al.  Reactive oxygen species in cancer cells: live by the sword, die by the sword. , 2006, Cancer cell.

[46]  E. Kern,et al.  In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. , 2006, Antiviral research.

[47]  S. K. Choudhuri,et al.  The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. , 2006, Chemico-biological interactions.

[48]  D. Richardson,et al.  The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer , 2005, Pharmacological Reviews.

[49]  M. Sznol,et al.  Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  D. Rorabacher,et al.  Electron transfer by copper centers. , 2004, Chemical reviews.

[51]  D. Gambino,et al.  The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes. , 2003, Mini reviews in medicinal chemistry.

[52]  Kevin Barraclough,et al.  I and i , 2001, BMJ : British Medical Journal.

[53]  W. Jäger,et al.  Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of (4)N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. , 2001, Journal of medicinal chemistry.

[54]  A. Sartorelli,et al.  Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. , 1999, Advances in enzyme regulation.

[55]  M. B. Pinto,et al.  Optimized δ expansion for relativistic nuclear models , 1997, nucl-th/9709049.

[56]  G. Huttner,et al.  Preparation and X-ray Crystal Structure of the First Trimeric Nickel Thiosemicarbazone Complex: The First Example of Oligomerization by both NiONi and NiSNi Bridging , 1996 .

[57]  S. Tsang,et al.  Research communication copper-1,10-phenanthroline induces internucleosomal DNA fragmentation in HepG2 cells, resulting from direct oxidation by the hydroxyl radical. , 1996, The Biochemical journal.

[58]  D. Petering,et al.  Oxidation-reduction reactions in Ehrlich cells treated with copper-neocuproine. , 1992, Free radical biology & medicine.

[59]  A. Sartorelli,et al.  Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. , 1992, Journal of medicinal chemistry.

[60]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[61]  D. Petering,et al.  Inhibition of iron uptake in HL60 cells by 2-formylpyridine monothiosemicarbazonato Cu(II). , 1991, Archives of biochemistry and biophysics.

[62]  D. Petering,et al.  Oxidative stress induced by a copper-thiosemicarbazone complex. , 1990, Biochemistry.

[63]  R. Schroeder,et al.  Evidence for a square scheme involving conformational intermediates in electron-transfer reactions of copper(II)/(I) systems , 1989 .

[64]  A. Fojo,et al.  Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. , 1988, Cancer research.

[65]  M. Botsivali,et al.  Studies on singlet oxygen in aqueous solution. Part 2. Water-soluble square-planar nickel complexes as quenchers , 1985 .

[66]  David J. Leggett,et al.  Computational methods for the determination of formation constants , 1985 .

[67]  A. W. Addison,et al.  Synthesis, structure, and spectroscopic properties of copper(II) compounds containing nitrogen–sulphur donor ligands; the crystal and molecular structure of aqua[1,7-bis(N-methylbenzimidazol-2′-yl)-2,6-dithiaheptane]copper(II) perchlorate , 1984 .

[68]  W. Antholine,et al.  Effects of 2-formylpyridine monothiosemicarbazonato copper II on red cell components. , 1984, Journal of inorganic biochemistry.

[69]  J. Felcman,et al.  Complexes of oxovanadium(IV) with polyaminocarboxylic acids. , 1983, Talanta.

[70]  K. Murray,et al.  Water-soluble cobalt(II) complexes of NN′-substituted bis(salicylaldimine-5-sulphonic acids). Oxygen-carrying properties and conversion into cobalt(III) organometallic compounds , 1982 .

[71]  D. Petering,et al.  Interaction of 2-formylpyridine thiosemicarbazonato copper (II) with Ehrlich ascites tumor cells. , 1981, Biochemical pharmacology.

[72]  F. Pavelčík,et al.  Crystal and molecular structure of the nickel(II) chelate of salicylidenethiosemicarbazone ammine - C 8 H 7 N 3 OSNi.NH 3 , 1981 .

[73]  R. Stephenson.  A and V , 1962, The British journal of ophthalmology.

[74]  H. Skipper,et al.  Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. , 1956, Cancer research.

[75]  M. Born.  Volumen und Hydratationswärme der Ionen , 1920 .